Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diosmin→

Diosmin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
520-27-4
Molecular formula
C28H32O15
Molecular weight
608.5 g/mol
Drug class
Flavonoid venotonic and vasoprotective agent (often supplied in micronised purified flavonoid fraction)
Mechanism of action
Reduces venous distensibility and venous stasis, improves venous tone, decreases capillary permeability and fragility, and supports lymphatic drainage. These effects are attributed to modulation of noradrenergic signalling and inflammatory mediators; the full molecular mechanism is not completely defined.
Indications / reported uses
  • Symptomatic treatment of chronic venous disease, including heaviness, pain and swelling of the legs, where authorised
  • Short-term treatment of symptoms of acute haemorrhoidal disease in product-authorised settings

Sources: UK SmPC — Daflon 500 mg (diosmin/hesperidin) · European Medicines Agency — diosmin/flavonoid class evidence overview · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diosmin Environmental Risk Assessment (ERA) (the Diosmin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.